MLabs Appoints Dr. Julia Dahl as new Associate Director
Ann Arbor, MI – MLabs (http://mlabs.umich.edu/) announced today that Dr. Julia Dahl has joined the laboratory to further develop their growing portfolio of regional and national accounts. Dr. Dahl comes with a wealth of experience in developing products and services around a patient centered vision including direct patient consultations and unique reporting solutions.
Dr. Dahl joins MLabs as the new Associate Director with experience as a former client who demonstrated the value that accrues from partnering with a reference laboratory like MLabs to bridge the gap between demands for subspecialty support in an acute care setting and the resources available to smaller pathology practices.
“She has championed the idea that pathology sits at the hub of a multidisciplinary system with opportunities to influence and drive the entire value stream from patient entry to treatment as a measure of diagnostic effectiveness.” Says Dr. Jeff Myers, MLab’s Director, “I am confident that Dr. Dahl will play a key role in helping us to transform the experience of our clients, their providers and most importantly their patients when it comes to driving tomorrow’s health care solutions with cutting edge personalized laboratory information and consultation.”
The Future of Comprehensive Precision Oncology Testing at MLabs:
The Michigan Center for Translational Pathology (MCTP), founded and directed by Dr. Arul Chinnaiyan at the University of Michigan Health System, is a pioneer in precision oncology, being one of the first groups to comprehensively profile advance cancers in a clinically-relevant time frame (see Sci Transl Med. 2011 Nov 30;3(111):111-121.) Building on its early successes, MCTP has continued to refine its testing approach and remains a leader in this dynamic field.
MCTP has developed two precision oncology assays that interrogate different numbers of cancer genes. Using their flagship assay, OncoSeq, MCTP has now profiled over 1,000 patients at the University of Michigan Comprehensive Cancer Center. Results from their pediatric cancer cohort was recently published (See JAMA. 2015 Sep 1;314(9):913-25) and they are currently evaluating their considerable experience in adults. The current version of OncoSeq interrogates around 1,700 cancer genes and has been adapted to both frozen and FFPE tissue samples.
MCTP has also developed the Oncomine Comprehensive Panel (OCP) under the direction of Dr. Scott Tomlins in collaboration with Life Technologies (see Neoplasia. 2015 Apr;17(4):385-99). This assay, focused on solid-tumor testing, interrogates 143 genes and was specifically designed to work with FFPE tissue samples. The OCP assay was selected by the National Cancer Institute (NCI) as the standard assay for the NCI-Match trials currently underway (see http://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match). MCTP will be launching the OCP assay in the coming months.
Our newest Comprehensive NGS Plan includes:
USCAP 2016. Join us at the largest meeting of physician-pathologists in the world between March 12-18, 2016 at the Washington State Convention Center in beautiful Seattle, Washington. This year will mark the 105th USCAP Annual Meeting which will focus on Next Generation Learning. You can visit MLab’s booth at #813. USCAP Meeting Site: http://www.uscap.org/meetings/detail/2016-annual-meeting
U-M Health System launches $160M project to improve lab tests for patients in Michigan and beyond. New facility at NCRC will house most pathology test & biopsy processing; rapid testing space on main medical campus to be renovated. Millions of times a year, teams at the University of Michigan Health System test samples of tissue, blood and other bodily fluids for patients of all ages. The results can reveal risks or signs of disease -- or response to treatment -- and help make a major difference in doctors’ decisions. A new $160 million project will give U-M’s clinical testing teams the best possible facilities to work in. It will allow them to continue giving patients and doctors the high-quality test results they seek, faster and with higher reliability. The U-M Board of Regents approved the project in a vote today. Now, UMHS will begin creating an entirely new 139,000-square-foot home for most of its clinical pathology activities, and renovating another 47,000 square feet of existing space. Read more here: http://www.uofmhealth.org/news/archive/201504/u-m-health-system-launches-160m-project-improve-lab-tests
Approval of Schematic Design: Clinical Pathology Laboratories Relocation and Renovation
At the April 2015 meeting, the Board of Regents approved the North Campus Research Complex (NCRC) Buildings 30, 35, 36 and 60, University Hospital, and University Hospital South Clinical Pathology Laboratories Relocation and Renovation project and the appointment ofTsoi/Kobus and Associates as the architect for its design. The goals of the project are to enhance the clinical laboratory functions necessary to meet present and future growth in test volumes, improve operational efficiency, and reduce the expense of having laboratories in multiple locations. Pathology laboratories currently located within University Hospital, University Hospital South, Medical Science Unit I, North Ingalls Building, and leased space will be relocated to NCRC Buildings 30, 35, 36 and 60. The Michigan Medical Genetics Laboratory of the Department of Pediatrics will also be relocated to NCRC. Read more here: http://mlabs.umich.edu/files/pdfs/2015-12-IX-15.pdf
New Genetic Testing Quality Initiative
The Department of Pathology is developing a new genetic testing quality initiative, underwritten by Blue Cross Blue Shield of Michigan. The Genetic Testing Resource and Quality Consortium will be a state-wide consortium of pathologists, primary care physicians, specialists, genetic counselors and pharmacogeneticists tasked with addressing the exponential growth in genetic testing and improving the quality of care for patients needing molecular diagnostic testing. A forum to introduce the GTRQC and to gather input will be held on February 17th, 4:00 – 6:00 pm at the NCRC, Building 300, Room 376. Pre-registration is required and a light meal will be provided. Register at www.gtrqc.org and select Forums > Ann Arbor Forum. Direct questions to Lynn McCain, Project Manager, at firstname.lastname@example.org or 734-763-2616.
Dr. Shih-Hon Li, fourth year AP/CP house officer, is the lead author of the article "Mechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1" which was published in the online early edition issue of Proceedings of the National Academy of Sciences, Dec 2, 2013. Dr. Daniel Lawrence, Frederick G. L. Huetwell Collegiate Professor of Basic Research in Cardiovascular Medicine, is the senior author. Additional authors include Dr. Jeanne Stuckey, Research Associate Professor of the LIfe Science Institute. The article can be found at http://www.pnas.org/content/early/2013/11/27/1216499110